Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35810754
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
/
Sequoia
/
COVID-19
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Type:
Article